Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewYM 202074 sesquifumarate
Discontinued Product
3413 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
说明： High affinity, selective mGlu1 antagonist
化学名： N-Cyclohexyl-6-[[N-(2-methoxyethyl)-N-methylamino]methyl]-N-methylthiazolo[3,2-a]benzoimidazole-2-carboxamide sesquifumarate
纯度： ≥99% (HPLC)
生物活性 for YM 202074 sesquifumarate
YM 202074 sesquifumarate is a high affinity, selective metabotropic glutamate receptor type 1 (mGlu1) antagonist. Binds an allosteric site of the rat mGlu1 receptor with a Ki of 4.8 nM. Inhibits mGlu1-mediated inositol phosphates production (IC50 = 8.6 nM in rat cerebellar granule cells). Neuroprotective in vivo.
技术数据 for YM 202074 sesquifumarate
| 分子量 | 588.67 |
| 公式 | C22H30N4O2S.1.5C4H4O4 |
| 储存 | Store at +4°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 299900-84-8 |
| PubChem ID | 90488842 |
| InChI Key | HABHEZNVNBKOQJ-VQYXCCSOSA-N |
| Smiles | CN(CCOC)CC1=CC=C2C(N(C=C(C(N(C)C4CCCCC4)=O)S3)C3=N2)=C1.O=C(O)/C=C/C(O)=O.O=C(O)/C=C/C(O)=O.O=C(O)/C=C/C(O)=O.CN(CCOC)CC5=CC=C6C(N(C=C(C(N(C)C8CCCCC8)=O)S7)C7=N6)=C5 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for YM 202074 sesquifumarate
参考文献 for YM 202074 sesquifumarate
参考文献是支持产品生物活性的出版物。
Kohara et al (2008) Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res. 1191 168 PMID: 18164695
Ferraguti et al (2008) Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol.Rev. 60 536 PMID: 19112153
Yanamoto et al (2010) Radiosynthesis and evaluation of [11C]YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1. Nucl.Med.Biol. 37 615 PMID: 20610166
关键词: YM 202074 sesquifumarate, YM 202074 sesquifumarate supplier, selective, YM202074, YM, 202074, sesquifumarate, metabotropic, glutamate, receptors, antagonists, mGluR1, mGlu, mGlu1, Group, I, Receptors, Glutamate, (Metabotropic), 3413, Tocris Bioscience
YM 202074 sesquifumarate 的评论
目前没有该产品的评论。 Be the first to review YM 202074 sesquifumarate and earn rewards!
Have you used YM 202074 sesquifumarate?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.